Change in multiple sclerosis prevalence over time in Australia 2010-2017 utilising disease-modifying therapy prescription data

doi:10.1177/1352458519861270

. 2020 Oct;26(11):1315-1328.

doi: 10.1177/1352458519861270. Epub 2019 Jul 26.

Change in multiple sclerosis prevalence over time in Australia 2010-2017 utilising disease-modifying therapy prescription data

Julie A Campbell¹, Steve Simpson Jr², Hasnat Ahmad¹, Bruce V Taylor¹, Ingrid van der Mei¹, Andrew J Palmer²

Affiliations

¹ Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia.
² Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia; Melbourne School of Population and Global Health, The University of Melbourne, Carlton, VIC, Australia.

PMID: 31347952
DOI: 10.1177/1352458519861270

Change in multiple sclerosis prevalence over time in Australia 2010-2017 utilising disease-modifying therapy prescription data

Julie A Campbell et al. Mult Scler. 2020 Oct.

. 2020 Oct;26(11):1315-1328.

doi: 10.1177/1352458519861270. Epub 2019 Jul 26.

Authors

Julie A Campbell¹, Steve Simpson Jr², Hasnat Ahmad¹, Bruce V Taylor¹, Ingrid van der Mei¹, Andrew J Palmer²

Affiliations

¹ Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia.
² Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia; Melbourne School of Population and Global Health, The University of Melbourne, Carlton, VIC, Australia.

PMID: 31347952
DOI: 10.1177/1352458519861270

Abstract

Objective: Determine the prevalence of multiple sclerosis (MS) in Australia in 2017 using MS-specific disease-modifying therapy (DMT) prescription data and estimate the change in prevalence from 2010.

Methods: DMT prescriptions were extracted from Australia's Pharmaceutical Benefits Scheme (PBS) data for January-December 2017. Percentages of people with MS using DMTs (DMT penetrance) were calculated using data from the Australian MS Longitudinal Study. Prevalence was estimated by dividing the total number of monthly prescriptions by 12 (except alemtuzumab), adjusted for DMT penetrance and Australian population estimates. Prevalences in Australian states/territories were age-standardised to the Australian population. Comparisons with 2010 prevalence data were performed using Poisson regression.

Results: Overall DMT penetrance was 64%, and the number of people with MS in Australia in 2017 was 25,607 (95% confidence interval (CI): 24,874-26,478), a significant increase of 4324 people since 2010 (p < 0.001). The prevalence increased significantly from 95.6/100,000 (2010) to 103.7/100,000 (2017), with estimates highest in Tasmania in 2017 (138.7/100,000; 95% CI: 137.2-140.1) and lowest in Queensland (74.6/100,000; 95% CI: 73.5-75.6). From 2010 to 2017 using the median latitudes for each state/territory, the overall latitudinal variation in MS prevalence was an increase of 3.0% per degree-latitude.

Conclusion: Consistent with global trends, Australia's MS prevalence has increased; this probably reflecting decreased mortality, increased longevity and increased incidence.

Keywords: Australian Multiple Sclerosis Longitudinal Study; Australian Pharmaceutical Benefits Scheme; health economics; immunomodulating agent.

PubMed Disclaimer

Cited by

Evaluation of multiple sclerosis severity using a new OCT tool.
Viladés E, Cordón B, Pérez-Velilla J, Orduna E, Satue M, Polo V, Sebastian B, Larrosa JM, Pablo L, García-Martin E. Viladés E, et al. PLoS One. 2023 Jul 13;18(7):e0288581. doi: 10.1371/journal.pone.0288581. eCollection 2023. PLoS One. 2023. PMID: 37440532 Free PMC article.
Validation of the EQ-5D-5L and psychosocial bolt-ons in a large cohort of people living with multiple sclerosis in Australia.
Campbell JA, Ahmad H, Chen G, van der Mei I, Taylor BV, Claflin S, Henson GJ, Simpson-Yap S, Laslett LL, Hawkes K, Hurst C, Waugh H, Palmer AJ. Campbell JA, et al. Qual Life Res. 2023 Feb;32(2):553-568. doi: 10.1007/s11136-022-03214-y. Epub 2022 Aug 29. Qual Life Res. 2023. PMID: 36036311 Free PMC article.
Exploring COVID-19 experiences for persons with multiple sclerosis and carers: An Australian qualitative study.
Correia H, Martin-Lynch P, Finlayson M, Learmonth YC. Correia H, et al. Health Expect. 2023 Apr;26(2):785-794. doi: 10.1111/hex.13704. Epub 2023 Jan 13. Health Expect. 2023. PMID: 36639883 Free PMC article.
Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition.
Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, Robertson N, La Rocca N, Uitdehaag B, van der Mei I, Wallin M, Helme A, Angood Napier C, Rijke N, Baneke P. Walton C, et al. Mult Scler. 2020 Dec;26(14):1816-1821. doi: 10.1177/1352458520970841. Epub 2020 Nov 11. Mult Scler. 2020. PMID: 33174475 Free PMC article.
Prevalence of chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy in two regions of Australia.
Park SB, Li T, Kiernan MC, Garg N, Wilson I, White R, Boggild M, McNabb A, Lee-Archer M, Taylor BV. Park SB, et al. Muscle Nerve. 2022 Nov;66(5):576-582. doi: 10.1002/mus.27698. Epub 2022 Aug 29. Muscle Nerve. 2022. PMID: 36054471 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

LinkOut - more resources

Full Text Sources
- Atypon
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Change in multiple sclerosis prevalence over time in Australia 2010-2017 utilising disease-modifying therapy prescription data

Affiliations

Change in multiple sclerosis prevalence over time in Australia 2010-2017 utilising disease-modifying therapy prescription data

Authors

Affiliations

Abstract

Similar articles

Cited by

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Medical